Biosimilars – Forecast – Respiratory
In 2021, sales of branded biologics for respiratory indications totaled about $0.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031 forecast period, biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Table of contents
- Biosimilars - Forecast - Respiratory
- Market forecast in the major pharmaceutical markets
- Major-market forecast: respiratory biologics in asthma
- Terminology
- Overarching forecast assumptions
- Overview of respiratory biological brands in forecast
- Overview of approved respiratory biologics in asthma
- Biosimilar entry assumptions for biologics in asthma
- Overview of biosimilars in respiratory disease assumptions
- Overview of respiratory biological brands in forecast
- Drug-specific forecast assumptions
- Xolair
- Outlook for Xolair
- First major-market biosimilar entrants
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturing price assumptions
- Xolair sales forecast for the United States: 2021-2031
- Xolair sales forecast for the EU5: 2021-2031
- Xolair sales forecast for Japan: 2021-2031
- Xolair
- Market forecast in the major pharmaceutical markets
Yashu Malhotra, M.Pharm., is an analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences department at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.